Bon Secours achieves breakthrough in advanced prostate cancer treatment

Bon Secours announced a major milestone in the fight against advanced prostate cancer – the successful delivery of our first Pluvicto™ therapy treatment. This powerful new therapy gives renewed hope to patients and families facing the challenges of metastatic prostate cancer.

Pluvicto is part of a new wave of cancer treatments known as molecular radioligand therapy. It’s a highly targeted treatment that uses advanced technology to find and attack cancer cells while leaving most healthy tissue untouched. By targeting a specific marker found on prostate cancer cells, this therapy delivers radiation directly to the disease with incredible precision.

This means fewer side effects and a more personalized, effective treatment experience for patients. Most importantly, it opens the door to better outcomes – helping patients live longer and feel better as they manage their condition.

“This groundbreaking development in the field of molecular radioligand therapy represents a transformative leap forward, instilling hope for our patients and their families grappling with this challenging diagnosis,” said Jennifer DelliSanti, CNMT, Nuclear Medicine Lead for Bon Secours. “Families can find reassurance in knowing that we are now equipped with this sophisticated treatment options that offer a personalized approach to care, catering to the circumstances and needs of each individual.”

This commitment to comprehensive care has earned the Bon Secours St. Francis Cancer Center high patient satisfaction scores, with many patients highlighting the compassionate and personalized approach they have experienced. With approximately $2 million in annual research funding and around 90 active clinical trials, the center is poised to continue its mission of delivering innovative treatments and improving patient outcomes well into the future.

“We are optimistic about the continued development of transformative therapies that will further strengthen our ability to combat this disease. Together, we can provide our patients and their families with renewed hope and a clearer path forward in their journey against metastatic prostate cancer,” said DelliSanti.

Odds are one in nine men will have prostate cancer at some point in their lives. To learn more about the condition and what resources Bon Secours has available, visit bonsecours.com.

About Bon Secours

Bon Secours St. Francis is part of Bon Secours Mercy Health (BSMH), one of the 20 largest health systems in the United States and the fifth-largest Catholic health system in the country. The ministry’s quality, compassionate care is provided by more than 60,000 associates serving communities in Florida, Kentucky, Maryland, New York, Ohio, South Carolina, and Virginia, as well as throughout Ireland. Bon Secours Mercy Health provides care for patients more than 11 million times annually through its network of more than 1,200 care sites, which includes 49 hospitals. In 2023, BSMH provided more than $600 million dollars in community investments across five states, ensuring that cost is not a barrier to health care for our patients in need. Locally, Bon Secours St. Francis provides compassionate medical care to thousands of area residents through Bon Secours St. Francis Downtown and Bon Secours St. Francis Eastside, as well as a network of primary and specialty care practices, and ambulatory care sites across the Greenville region. The mission of Bon Secours St. Francis is to extend the compassionate ministry of Jesus by improving the health and well-being of our communities and bring good help to those in need, especially people who are poor, dying and underserved. For more information, visit BonSecours.com.